Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
MIVACRON (mivacurium chloride) is a short-acting depolarizing neuromuscular blocking agent administered intravenously for anesthesia. It is used during surgery to facilitate endotracheal intubation and provide skeletal muscle relaxation during operative procedures. The drug works by binding to acetylcholine receptors at the neuromuscular junction, causing depolarization and temporary paralysis.
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a contracting commercial team and focus on retention strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MIVACRON offers limited active career growth opportunities given its LOE-approaching lifecycle stage and minimal linked job postings. Roles available focus on defending market share, managing formulary relationships, and preparing for generic competition rather than expansion or innovation.
Worked on MIVACRON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.